Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PELICAN: Pembrolizumab + Paclitaxel in Luminal B Breast Cancer
NCT03841747Phase 2Withdrawn
- Sponsor
- Queen Mary University of London
- Start
- Dec 2020
- Primary completion
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of pembrolizumab in breast cancer, sponsored by Queen Mary University of London. Planned start Dec 2020; status: withdrawn.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03841747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03841747.